Objective: This study aimed to examine the safety of 5-aminolevulinic acid phosphate (5-ALA) with sodium ferrous citrate (SFC) in diabetic patients treated with one or more oral hypoglycemic agents (OHAs).
Disease exacerbation caused by dietary supplements has become a growing concern in Japan, so it is critical to examine the safety of dietary supplements in patients in addition to healthy subjects.
It has recently been shown that a dietary supplement, 5-aminolevulinic acid phosphate (5-ALA) with sodium ferrous citrate (SFC), reduces blood glucose level in pre-diabetic populations without adverse events in the USA and Japan [12, 13] . 5-ALA is a natural amino acid and it is a precursor of heme, a major compartment of hemoglobin and myoglobin. 5-ALA is also an essential constituent of cytochromes and thus, it is important for cellular energy production in mitochondria [14] . It has been shown that exogenously applied 5-ALA with SFC increases the activity of complex IV in the mitochondrial electron transport chain in experimental animals [14] and increases the basal metabolic rate and suppresses fat accumulation in rats [15] . These findings appear to be compatible with the blood glucose lowering effect of pre-diabetes in humans [12, 13] . Therefore if diabetic patients take 5-ALA supplement in addition to OHAs or insulin, there might be a risk of reducing blood glucose to a level that triggers hypoglycemia (hypoglycemic attack). Since 5-ALA is readily accessible to diabetic patients without a physician's prescription, it is desirable to obtain the safety test data of 5-ALA in these patients. Based on this consideration the present study was performed.
METHODS:
Study design. This study was a prospective single-blinded, randomized, placebo-controlled and parallel-group comparison study. The study protocol was approved by the Institutional Review Board (IRB) of the Institute of Medical Science, University of Tokyo, Japan and registered to University Hospital Medical Information Network (UMIN) as UMIN000008038.
Diabetic patients treated with one or more OHAs were recruited from the patient panel of TES Holdings Co. Ltd. by internet advertisement. Total number of the registered patients was about 1000 and 81 candidates applied to this study from Tokyo metropolitan area of Japan.
OHAs included sulfonylurea, DPP-4 inhibitor, α-glucosidase inhibitor, metformin, pioglitazone, glinide and GLP-1 analogue. The inclusion criteria for the diabetic patients were: (1) between the ages of 30 and 75 from whom written consent was obtained, (2) treated with OHAs, (3) without hypoglycemic attack for 3 months before inclusion, and (4) whose diabetic medication not to be altered during the study period. The exclusion criteria for the diabetic patients were: (1) treated with insulin, (2) with porphyria, hemochromatosis or viral hepatitis, (3) pregnant or possibly pregnant, (4) photo-hypersensitive, (5) enrolled in another clinical trial, or had a history of enrollment in another trial in the past 3 months, (6) taking anti-convulsant, anti-arrhythmic agents or coronary vasodilators, (7) allergic to drugs or food, (8) severely anemic (hemoglobin (Hb) < 8 mg/dl), (9) uncontrolled dependent on alcohol, and (10) severely psychotic patients. Patients deemed inappropriate to this study were judged by the principal investigator.
Primary endpoint of this study was safety and occurrence of hypoglycemic attack (defined by symptoms including abnormal sensation of hunger, anxiety, palpitation, sweating, and tremor, which could be improved by glucose ingestion). Secondary endpoint was the changes of FBG and HbA1c. The study period was from July 2012 to June 2013, and data were finally Statistical Analysis. With regard to the occurrence of hypoglycemic attack, differences among three groups were examined by Fisher's exact test. Differences in blood glucose and HbA1c were examined by two way factorial analysis of variance. Differences in quantitative data of blood count and chemistry were examined by two way factorial analysis of variance, and difference in qualitative data was examined by Fisher's exact test.
RESULTS:
Characteristics of patients in the present study are shown in Table 1 . Age and sex, and the baseline body weight, BMI, systolic & diastolic blood pressure, and heart rate were not significantly different among three groups. The numbers of oral hypoglycemic agents were 2.13 ± 1.03 (mean ± SD) in the 15 mg 5-ALA group, 2.00 ± 1.00 in the 50 mg 5-ALA group, and 1.93 ± 0.91 in the control group. Content of oral hypoglycemic agents and the number of patients are shown in Table 1 . significantly different among the groups. Representable data are shown in Table 2 . Evaluation of the primary endpoint (safety and hypoglycemic attack) was performed on candidates who took 5-ALA with SFC more than once, and that of the secondary endpoint was performed for those who completed the entire study. The primary endpoint could be assessed in all 45 subjects while the secondary endpoint could be assessed in 37 subjects. The numbers of dropout subjects were two in the 15 mg 5-ALA group, five in the 50 mg 5-ALA group, and one in the control group.
The reasons for dropout were changes of oral hypoglycemic agents determined by the physician in charge, difficulty to continue visit for this study or occurrence of transient ischemic attack (TIA). was carried out. After 6 days he was recovered and discharged. This event was categorized as a serious adverse event and it was reported to IRB. However, since this subject belonged to the control group this adverse event was not related to 5-ALA with SFC. No adverse events related to 5-ALA with SFC was observed in the test groups. Abnormalities in blood and urine tests were not observed.
The secondary endpoint of this study was the change of FBG and HbA1c. It was evaluated in 13 subjects in the 15 mg 5-ALA group, 10 subjects in the 50 mg 5-ALA group, and 14 subjects in the control group (the number of subjects is different between Table 1 and Table 3 ).
Significant decrease in FBG was not detected in all groups but a small increase at week 12 in the 50 mg 5-ALA group was observed (Table 3) . A small but significant decrease in HbA1c was found at week 4 and 8 in the 15 mg 5-ALA group. Serum insulin levels appeared to decrease at week 4, 8, and 12 in the 15 mg 5-ALA group, but the change was not statistically significant. A significant decrease in HbA1c was not observed in the 50 mg 5-ALA group, although it showed a tendency to decrease after 4 weeks. indicates the hemoglobin concentration and the abscissa (HbA1c), HbA1c level. Each point corresponds to the data from one subject who completed the study. Some symbols overlapped each other among subjects.
Since 5-ALA is a precursor of heme and SFC was included in the supplement, it was plausible to speculate that the intake of this supplement would have changed Hb, which, in turn, affected the HbA1c level. However, no significant changes of serum iron and Hb were observed during the study period among all the groups. We further analyzed the relationship between Hb and HbA1c, and that between glycosylated albumin and HbA1c. As shown in Figure 1 , there was little correlation between Hb and HbA1c. On the contrary, HbA1c was strongly correlated to glycosylated albumin, which is not affected by serum iron or Hb [16] (Figure 2 ). These results indicate that HbA1c correctly represented the changes of blood glucose level. Each point corresponds to the data from one subject who completed the study. Some symbols overlapped each other among subjects
DISCUSSION:
The results of the present study showed that the supplemental use of 5-ALA with SFC appears to be safe for diabetic patients who are treated with OHAs. However the number of the subjects in this study is small, a larger scale study is necessary to draw a clear conclusion. In the Hawaii study (n=154), 5-ALA with SFC significantly reduced blood glucose level after a two h oral glucose tolerant test (OGTT) in pre-diabetic participants [12] . The effect was especially prominent among the subjects with baseline of two h OGTT levels greater than 140 mg/dl both in the 15 mg and 50 mg 5-ALA groups. In the Hiroshima study (n=212), 15 mg 5-ALA with SFC significantly reduced all of the fasting glucose level, glycosylated albumin, and blood glucose level after two h of OGTT in mildly hyperglycemic participants [13] . Thus, it has been demonstrated that 5-ALA with SFC improves glucose metabolism in pre-diabetic subjects.
5-ALA with SFC is a supplement available at drug stores without a doctor's prescription and therefore it is probable that medically treated diabetic patients purchase this supplement, and take it in addition to prescribed drugs. In such occasion, the additional use of 5-ALA with SFC might lead to hypoglycemia or other adverse effects in diabetic patients who are under medical treatment. Therefore, the purpose of our study was designated to examine the safety and the occurrence of hypoglycemic attack. Our study revealed adverse events were not triggered by 5-ALA with SFC with absence of hypoglycemic attack in type II diabetes patients who were under medicinal treatment with OHAs.
The HbA1c level, which was set as the secondary end point in this study, was significantly reduced at 4 and 8 weeks in the 15 mg 5-ALA group. Serum insulin did not increase at 4 or 8 weeks but rather decreased during these periods, suggesting that 5-ALA improved the glucose metabolism via insulin-independent fashion. HbA1c showed a decrease in the 50 mg 5-ALA group but the change was not statistically significant. The average decrease in HbA1c by 5-ALA with SFC was less than 0.25% (range: 0.03-0.25%). It has been previously reported that the reduction of HbA1c was from 0.2 to 2% by metformin [17] , 0.5 to 1.5% by sulfonylurea [17, 18] , that by α-glucosidase inhibitor, up to 1% [17] , that by DPP-4 inhibitors, 0.6 to 1% [19] [20] [21] [22] , and 0.5 to 1.1% by GLP-1 analogue [22] . Furthermore a meta-analysis of the treatment of type II diabetes with dietary fiber has revealed that intervention by dietary fiber had an effect of HbA1c
with an average decrease of 0.26% [23] , while another meta-analysis of dietary supplement cinnamon showed a 0.09 % decrease in mean HbA1c [24] . Taken together, the effect of 5-ALA with SFC on HbA1c in diabetic patients appears to be lower than those by OHAs and comparable to dietary supplements. It has been long established that exercise and diet are beneficial to diabetes mellitus. Exercise for more than 8 months significantly reduces HbA1c by 0.66% without significant decrease of body weight [25] . Nutrition therapy was shown to be able to reduce HbA1c by 1 to 2% in type II diabetic patients [26, 27] . Thus, exercise and diet are very effective to control blood glucose level in diabetes. This observation was applicable even in the case in healthy people and pre-diabetic subjects.
In the present study, the intake of 5-ALA with SFC did not alter serum iron concentration and Hb. Therefore, the decrease of HbA1c by 5-ALA with SFC was not ascribed to the change of Hb. It was apparent that there was a close relationship between HbA1c and glycosylated albumin as shown in this study, and therefore it was considered that HbA1c correctly reflected the change of blood glucose level. Although HbA1c significantly decreased after 4 and 8 weeks in the 15 mg 5-ALA group, no significant change was observed in glycosylated albumin. It was speculated that probably HbA1c is sensitive to blood glucose alteration more than glycosylated albumin. In the Hiroshima study, 5-ALA significantly decreased the glycosylated albumin in pre-diabetic subjects, but no significant change was observed in HbA1c [13] . The authors discussed that glycosylated albumin reflects the rapid change of blood glucose levels as compared to HbA1c, and that glycosylated albumin reflects postprandial glucose change better than HbA1c, which is represented by the significant decrease of the glucose level at two h of OGTT [13] . In the Hawaii study, there was a tendency that 5-ALA with SFC decreased HbA1c in pre-diabetic subjects although it was not statistically significant (p=0.07) [12] . Glycosylated albumin also tended to decrease by 5-ALA with SFC, but similar to our study, it appeared that HbA1c was more sensitive than glycosylated albumin (p=0.22). However it is a premature state to at present to speculate the cause for the discrepancy of the relationship between HbA1c and glycosylated albumin among three studies.
5-ALA with SFC has been shown to increase the metabolic rate in rats [15] and humans would decrease body weight, but a significant decrease was not detected in either of the 5-ALA groups. Because the duration of the test period was 12 weeks, a longer application of 5-ALA might possibly exert some effect on body weight. It is also possible that body weight change may not be clearly detected in Japanese diabetic patients, because more than half of the diabetic patients are non-obese [28] as in other East Asian countries [29] .
In summary, 5-ALA with SFC can be safely taken by diabetic patients treated with OHAs.
5-ALA with SFC showed some activity on HbA1c in diabetic patients, but the symptoms ascribed to hypoglycemia were not observed. The number of applicants and test period were limited in this study, and a larger scale and longer follow-up study are deemed necessary to establish the safety of 5-ALA with SFC and its effect on glucose metabolism in diabetic patients. 
